Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: A pilot study

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Benson, Eric A ^a   Skaar, Todd C ^a,b   Liu, Yunlong ^a   Nephew, Kenneth P ^a,b   Matei, Daniela ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DECITABINE; MICRORNA; MICRORNA 10A 5P; MICRORNA 133A 3P; MICRORNA 148B 5P; MICRORNA 193A 5P; MICRORNA 25 3P; MICRORNA 339 3P; MICRORNA 340 5P; MICRORNA 375; MICRORNA 532 3P; MICRORNA 616 5P; PEGFILGRASTIM; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZACITIDINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CANCER STAGING; CLINICAL TRIAL; DRUG RESISTANCE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BIOMARKERS, TUMOR; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84949293174     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141279     Document Type: Article

References (29)

1. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Advances in anatomic pathology. 2009; 16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa PMID: 19700937
2. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. Journal of oncology. 2010; 2010:932371. doi: 10.1155/2010/932371 PMID: 19746182
3. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecologic oncology. 2010; 119(1):7-17. doi: 10.1016/j.ygyno. 2010.06.003 PMID: 20692025
4. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014; 8(1):59-67. doi: 10.1016/j.molonc.2013.09.001 PMID: 24119443
5. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews Cancer. 2006; 6(4):259-69. PMID: 16557279
6. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. The international journal of biochemistry & cell biology. 2010; 42(8):1262-72.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. PMID: 15944708
8. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein & cell. 2012; 3(1):28-37.
9. Benson EA, Skaar TC. Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. Drug metabolism and disposition: the biological fate of chemicals. 2013; 41(10):1778-81.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(30):10513-8. doi: 10.1073/pnas.0804549105 PMID: 18663219
11. Zhao YN, Chen GS, Hong SJ. Circulating MicroRNAs in gynecological malignancies: from detection to prediction. Experimental hematology & oncology. 2014; 3:14.
12. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PloS one. 2013; 8(11):e77853. doi: 10.1371/journal.pone.0077853 PMID: 24223734
13. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014; 33(3):378-86. doi: 10.1038/onc.2012.575 PMID: 23318422
14. Zhao HM, Wei W, Sun YH, Gao JH, Wang Q, Zheng JH. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. Tumour Biol. 2015.
15. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecologic oncology. 2009; 114(2):253-9. doi: 10.1016/j.ygyno. 2009.04.024 PMID: 19446316
16. Frederick PJ, Green HN, Huang JS, Egger ME, Frieboes HB, Grizzle WE, et al. Chemoresistance in ovarian cancer linked to expression of microRNAs. Biotech Histochem. 2013; 88(7):403-9. doi: 10. 3109/10520295.2013.788736 PMID: 23672416
17. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer research. 2012; 72(9):2197-205. doi: 10.1158/0008-5472.CAN-11-3909 PMID: 22549947
18. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer research. 2000; 60(21):6039-44. PMID: 11085525
19. Nakano H, Yamada Y, Miyazawa T, Yoshida T. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. International journal of oncology. 2013; 42(6):1875-82. doi: 10.3892/ijo.2013.1896 PMID: 23588298
20. Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. Journal of translational medicine. 2012; 10:241. doi: 10.1186/1479-5876-10-241 PMID: 23217102
21. Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Molecular medicine reports. 2012; 5(5):1277-80. doi: 10. 3892/mmr.2012.794 PMID: 22344713
22. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. doi: 10.1038/nature10166 PMID: 21720365
23. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PloS one. 2012; 7(3):e34546. doi: 10.1371/journal.pone.0034546 PMID: 22479643
24. Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, et al. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 2015; 6-(4):2397-406. PMID: 25537514
25. Wen Z, Zhao S, Liu S, Liu Y, Li X, Li S. MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. Molecular medicine reports. 2015.
26. Zhao S, Wen Z, Liu S, Liu Y, Li X, Ge Y, et al. MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3. Molecular medicine reports. 2015.
27. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y, et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncology reports. 2012; 27(2):447-54. doi: 10.3892/or.2011.1482 PMID: 21971665
28. Gezer U, Keskin S, Igci A, Tukenmez M, Tiryakioglu D, Cetinkaya M, et al. Abundant circulating micro-RNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. Oncology letters. 2014; 8(2):845-8. PMID: 25009660
29. Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast cancer research and treatment. 2014; 147(1):61-8. doi: 10.1007/s10549-014-3079-3 PMID: 25086636